2019
DOI: 10.1016/j.ijbiomac.2019.07.003
|View full text |Cite
|
Sign up to set email alerts
|

Potential effect of carnosine encapsulated niosomes in bovine serum albumin modifications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 19 publications
(10 citation statements)
references
References 73 publications
0
10
0
Order By: Relevance
“…By employing a rodent model of diet-induced obesity and metabolic syndrome, the authors demonstrated the ability of carnosinol to dose-dependently attenuate 4-hydroxynonenal adduct formation in liver and skeletal muscle, while simultaneously mitigating inflammation, dyslipidemia, insulin resistance, and steatohepatitis. As described by Grasso et al [ 136 ], alternative approaches to increase carnosine delivery and its bioavailability include the use of carnosine derivatives [ 137 , 138 , 139 ]; vesicular systems (nanoliposomes, niosomes, and polymerosomes) [ 140 , 141 , 142 , 143 ]; and nanoparticulate systems [ 144 , 145 , 146 , 147 ]. The currently “under-used” intranasal administration route might also represent an innovative approach, since it can purportedly bypass the BBB and first-pass metabolism [ 148 , 149 ]; the vasodilatory activity of carnosine [ 150 ] also makes this endogenous dipeptide an attractive candidate for this kind of delivery.…”
Section: In Vivo Preclinical Studies: Administration Route Dosage Tre...mentioning
confidence: 99%
“…By employing a rodent model of diet-induced obesity and metabolic syndrome, the authors demonstrated the ability of carnosinol to dose-dependently attenuate 4-hydroxynonenal adduct formation in liver and skeletal muscle, while simultaneously mitigating inflammation, dyslipidemia, insulin resistance, and steatohepatitis. As described by Grasso et al [ 136 ], alternative approaches to increase carnosine delivery and its bioavailability include the use of carnosine derivatives [ 137 , 138 , 139 ]; vesicular systems (nanoliposomes, niosomes, and polymerosomes) [ 140 , 141 , 142 , 143 ]; and nanoparticulate systems [ 144 , 145 , 146 , 147 ]. The currently “under-used” intranasal administration route might also represent an innovative approach, since it can purportedly bypass the BBB and first-pass metabolism [ 148 , 149 ]; the vasodilatory activity of carnosine [ 150 ] also makes this endogenous dipeptide an attractive candidate for this kind of delivery.…”
Section: In Vivo Preclinical Studies: Administration Route Dosage Tre...mentioning
confidence: 99%
“…As such, preventive approaches for minimizing the formation of nonenzymatic glycation is of great importance. Among the compounds with deglycation activity, peptides such as carnosine and its analogs are especially studied (Moulahoum et al., 2019). Targeting diabetic complications by the inhibition of nonenzymatic glycation at different levels such as Schiff base, advanced glycation end‐products (AGE), and protein aggregation is very important.…”
Section: Resultsmentioning
confidence: 99%
“…Increased levels of AOPPs and AGEs are found in amyloid plaques in AD brains, 70 and modifications such as the formation of AGEs and AOPPs may contribute to protein aggregation and amyloid fibril formation, and subsequent cognitive impairment. 71,72 Notably, MR significantly decreased the level of the AD-related biomarker Aβ-40 in D-Gal-induced aging mice (Fig. 10).…”
Section: Food and Function Papermentioning
confidence: 89%